A biotech in­cu­bat­ed by RA Cap­i­tal has se­cured a $57.5 mil­lion Se­ries B to be­gin a mid-stage tri­al for its car­dio drug this quar­ter and … ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics' near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

“It is no use asking for the impossible, such as, say, the exact wiring diagram for a cubic millimeter of brain tissue and the way all its neurons are firing,” Crick wrote in Scientific America ...

Get Instant Summarized Text (Gist) A comprehensive wiring diagram and functional map of a mouse brain's visual cortex, the largest to date, has been created from a cubic millimeter of tissue. This ...

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...

Cytokinetics CYTK is a potential competitor for Edgewise Therapeutics in the market for HCM drugs. A regulatory filing seeking the approval of CYTK’s lead candidate in the cardiac muscle ...

SAN DIEGO — The American Academy of Neurology honored Merit E. Cudkowicz, MD, MSc, FAAN, with its Lifetime Achievement Award for her extensive work in ALS research. “I have really been blessed ...

On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of Cytokinetics (NASDAQ:CYTK), with a focus on the company’s heart failure treatment, Afi™. While the stock is ...

Shares of Cytokinetics, one of Edgewise's competitors, surged in response. Edgewise Therapeutics (EWTX) shares tumbled more than 20% Wednesday after the developmental drug company issued the ...

Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ:CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...